Document
false--12-31Q120190000764180falseLarge Accelerated Filerfalsemo12260000000600000010000005000000200000010000004000000800000020000001000000100000010000004000000100000020000001600000080000001000000200000010000001200000010000008000000700000020000003000000120000002100000000100000005000000001000000200000001600000090000003000000016000000050000001000000020000000100000000.70.80.33330.333328059613172805961317P5Y2.273.942470000001000000012000000200000010000006000000200000001000000010000001000000100000010000005000000100000010000004200000030000001100000080000002100000011000000500000020000004000000200000032500060000001000000179000000931903722934207054
0000764180
2019-01-01
2019-03-31
0000764180
2019-04-15
0000764180
2018-12-31
0000764180
2019-03-31
0000764180
2018-01-01
2018-03-31
0000764180
us-gaap:RetainedEarningsMember
2019-01-01
2019-03-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-03-31
0000764180
us-gaap:TreasuryStockMember
2019-01-01
2019-03-31
0000764180
us-gaap:NoncontrollingInterestMember
2018-12-31
0000764180
us-gaap:TreasuryStockMember
2019-03-31
0000764180
us-gaap:CommonStockMember
2019-03-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-12-31
0000764180
us-gaap:NoncontrollingInterestMember
2019-03-31
0000764180
us-gaap:TreasuryStockMember
2018-12-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-03-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2018-12-31
0000764180
us-gaap:RetainedEarningsMember
2019-03-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-03-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2019-03-31
0000764180
us-gaap:CommonStockMember
2018-12-31
0000764180
us-gaap:RetainedEarningsMember
2018-12-31
0000764180
us-gaap:TreasuryStockMember
2017-12-31
0000764180
us-gaap:CommonStockMember
2017-12-31
0000764180
us-gaap:CommonStockMember
2018-03-31
0000764180
2017-12-31
0000764180
us-gaap:RetainedEarningsMember
2018-01-01
2018-03-31
0000764180
us-gaap:TreasuryStockMember
2018-01-01
2018-03-31
0000764180
us-gaap:RetainedEarningsMember
2017-12-31
0000764180
us-gaap:TreasuryStockMember
2018-03-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2018-03-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-03-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2018-01-01
2018-03-31
0000764180
us-gaap:NoncontrollingInterestMember
2018-03-31
0000764180
us-gaap:AdditionalPaidInCapitalMember
2017-12-31
0000764180
us-gaap:NoncontrollingInterestMember
2017-12-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2017-12-31
0000764180
2018-03-31
0000764180
us-gaap:RetainedEarningsMember
2018-03-31
0000764180
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-01-01
2018-03-31
0000764180
mo:JUULMember
2018-12-01
2018-12-31
0000764180
mo:ABInBevMember
2019-03-31
0000764180
mo:JUULMember
2019-03-31
0000764180
mo:CronosGroupInc.Member
2019-03-08
0000764180
us-gaap:AccountingStandardsUpdate201602Member
2019-01-01
0000764180
mo:January2018ShareRepurchaseProgramMember
2018-05-31
0000764180
mo:July2015ShareRepurchaseProgramMember
2016-10-31
0000764180
mo:CronosGroupInc.Member
2019-01-01
2019-03-31
0000764180
mo:CronosGroupInc.Member
2019-03-31
0000764180
mo:July2015ShareRepurchaseProgramMember
2017-07-31
0000764180
mo:JUULMember
2018-12-31
0000764180
mo:July2015ShareRepurchaseProgramMember
2015-07-01
2018-01-31
0000764180
mo:January2018ShareRepurchaseProgramMember
2019-03-31
0000764180
mo:January2018ShareRepurchaseProgramMember
2018-01-31
0000764180
mo:July2015ShareRepurchaseProgramMember
2015-07-31
0000764180
us-gaap:OperatingSegmentsMember
mo:SmokeableProductsMember
2018-01-01
2018-03-31
0000764180
us-gaap:CorporateNonSegmentMember
2019-01-01
2019-03-31
0000764180
us-gaap:OperatingSegmentsMember
mo:SmokelessProductsMember
2019-01-01
2019-03-31
0000764180
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2018-01-01
2018-03-31
0000764180
us-gaap:OperatingSegmentsMember
mo:SmokelessProductsMember
2018-01-01
2018-03-31
0000764180
us-gaap:CorporateNonSegmentMember
2018-01-01
2018-03-31
0000764180
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-03-31
0000764180
us-gaap:OperatingSegmentsMember
mo:SmokeableProductsMember
2019-01-01
2019-03-31
0000764180
mo:CostReductionProgramMember
2018-12-01
2018-12-31
0000764180
us-gaap:OtherRestructuringMember
mo:CostReductionProgramMember
2019-03-31
0000764180
mo:CostReductionProgramMember
2019-01-01
2019-03-31
0000764180
mo:CostReductionProgramMember
2018-12-31
0000764180
us-gaap:EmployeeSeveranceMember
mo:CostReductionProgramMember
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
2019-03-31
0000764180
mo:ABInBevMember
2018-12-31
0000764180
mo:ABInBevMember
2018-01-01
2018-12-31
0000764180
mo:ABInBevMember
2019-01-01
2019-03-31
0000764180
mo:CronosGroupInc.Member
us-gaap:CommonStockMember
2019-03-31
0000764180
mo:EquityContractWarrantMember
2019-03-31
0000764180
mo:ABInBevMember
2018-12-31
0000764180
mo:CronosGroupInc.Member
2018-12-31
0000764180
mo:JUULMember
2018-12-20
2018-12-20
0000764180
mo:CronosGroupInc.Member
2019-03-08
2019-03-08
0000764180
mo:CronosGroupInc.Member
mo:EquityContractWarrantMember
2019-03-08
2019-03-08
0000764180
mo:CronosGroupInc.Member
mo:EquityContractWarrantMember
2019-03-08
0000764180
mo:CronosGroupInc.Member
mo:EquityContractPreemptiveRIghtsMember
2019-03-08
2019-03-08
0000764180
mo:CronosGroupInc.Member
mo:EquityContractPreemptiveRIghtsMember
2019-03-31
0000764180
mo:CronosGroupInc.Member
mo:EquityContractPreemptiveRIghtsMember
2019-03-08
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2019-01-01
2019-03-31
0000764180
mo:ForeignCurrencyDenominatedDebtMember
us-gaap:NetInvestmentHedgingMember
2019-01-01
2019-03-31
0000764180
mo:ForeignCurrencyDenominatedDebtMember
us-gaap:NetInvestmentHedgingMember
2018-01-01
2018-03-31
0000764180
us-gaap:NetInvestmentHedgingMember
2019-01-01
2019-03-31
0000764180
us-gaap:NetInvestmentHedgingMember
2018-01-01
2018-03-31
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2018-01-01
2018-03-31
0000764180
us-gaap:NetInvestmentHedgingMember
2019-03-31
0000764180
us-gaap:OtherAssetsMember
mo:EquityContractWarrantMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2019-03-31
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-03-31
0000764180
us-gaap:OtherAssetsMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-03-31
0000764180
mo:OtherAccruedLiabilitiesMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-03-31
0000764180
us-gaap:OtherAssetsMember
mo:EquityContractPreemptiveRIghtsMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2018-12-31
0000764180
us-gaap:EquityContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2018-12-31
0000764180
us-gaap:EquityContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2019-03-31
0000764180
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000764180
mo:OtherAccruedLiabilitiesMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000764180
us-gaap:OtherAssetsMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000764180
us-gaap:OtherAssetsMember
mo:EquityContractWarrantMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2018-12-31
0000764180
us-gaap:OtherLiabilitiesMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000764180
us-gaap:OtherCurrentAssetsMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-03-31
0000764180
us-gaap:OtherAssetsMember
mo:EquityContractPreemptiveRIghtsMember
us-gaap:NetInvestmentHedgingMember
us-gaap:NondesignatedMember
2019-03-31
0000764180
us-gaap:OtherLiabilitiesMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-03-31
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000764180
us-gaap:OtherCurrentAssetsMember
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000764180
us-gaap:EquityContractMember
us-gaap:FairValueInputsLevel3Member
2018-12-31
0000764180
us-gaap:EquityContractMember
us-gaap:FairValueInputsLevel3Member
2019-01-01
2019-03-31
0000764180
us-gaap:EquityContractMember
us-gaap:FairValueInputsLevel3Member
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputPriceVolatilityMember
2019-03-08
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputExpectedDividendRateMember
2019-03-08
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputExpectedDividendRateMember
2019-03-31
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputPriceVolatilityMember
2019-03-31
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputPriceVolatilityMember
2019-03-08
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2019-03-08
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputPriceVolatilityMember
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2019-03-08
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2019-03-08
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2019-03-31
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2019-03-31
0000764180
mo:ForeignCurrencyDenominatedDebtMember
2019-03-31
0000764180
us-gaap:ForwardContractsMember
us-gaap:NondesignatedMember
2019-01-01
2019-03-31
0000764180
mo:ForeignCurrencyDenominatedDebtMember
2018-12-31
0000764180
srt:MinimumMember
mo:EquityContractPreemptiveRIghtsMember
mo:MeasurementInputWeightedAverageExpectedTermMember
2019-03-31
0000764180
mo:EquityContractPreemptiveRIghtsMember
2019-01-01
2019-03-31
0000764180
us-gaap:ForwardContractsMember
us-gaap:NondesignatedMember
2019-03-08
0000764180
srt:MaximumMember
mo:EquityContractPreemptiveRIghtsMember
mo:MeasurementInputWeightedAverageExpectedTermMember
2019-03-31
0000764180
mo:EquityContractWarrantMember
2019-01-01
2019-03-31
0000764180
us-gaap:ForeignExchangeContractMember
us-gaap:NetInvestmentHedgingMember
2018-12-31
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputExpectedTermMember
2019-03-08
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputExpectedTermMember
2019-03-08
0000764180
mo:EquityContractPreemptiveRIghtsMember
us-gaap:MeasurementInputExpectedTermMember
2019-03-31
0000764180
mo:EquityContractWarrantMember
us-gaap:MeasurementInputExpectedTermMember
2019-03-31
0000764180
us-gaap:PensionPlansDefinedBenefitMember
2019-01-01
2019-03-31
0000764180
us-gaap:PensionPlansDefinedBenefitMember
2018-01-01
2018-03-31
0000764180
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-01-01
2018-03-31
0000764180
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-01-01
2019-03-31
0000764180
srt:MaximumMember
us-gaap:PensionPlansDefinedBenefitMember
2019-03-31
0000764180
srt:MaximumMember
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-03-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2019-01-01
2019-03-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2019-01-01
2019-03-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2018-12-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2019-03-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2019-03-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2018-12-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2018-12-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2019-03-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2018-01-01
2018-03-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2018-01-01
2018-03-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2017-12-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2018-01-01
2018-03-31
0000764180
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2018-03-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2018-03-31
0000764180
us-gaap:AccumulatedTranslationAdjustmentMember
2017-12-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2018-03-31
0000764180
mo:AccumulatedEquityMethodInvestmentsAttributableToParentMember
2017-12-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember
2018-01-01
2018-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2018-01-01
2018-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2018-01-01
2018-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2019-01-01
2019-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember
2019-01-01
2019-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember
2018-01-01
2018-03-31
0000764180
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonParticipatingManufacturerArbitrationPanelDecisionMember
us-gaap:OperatingIncomeLossMember
mo:NpmAdjustmentToCostOfSalesMember
mo:SmokeableProductsMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
us-gaap:MaterialReconcilingItemsMember
mo:TobaccoandHealthLitigationCasesMember
mo:InterestAndOtherDebtExpenseNetMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
us-gaap:OperatingSegmentsMember
mo:TobaccoandHealthLitigationCasesMember
us-gaap:OperatingIncomeLossMember
mo:SmokeableProductsMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:TobaccoandHealthLitigationCasesMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
us-gaap:MaterialReconcilingItemsMember
mo:TobaccoandHealthLitigationCasesMember
mo:InterestAndOtherDebtExpenseNetMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:TobaccoandHealthLitigationCasesMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
us-gaap:OperatingSegmentsMember
mo:TobaccoandHealthLitigationCasesMember
us-gaap:OperatingIncomeLossMember
mo:SmokeableProductsMember
2019-01-01
2019-03-31
0000764180
mo:WineMember
2018-01-01
2018-03-31
0000764180
mo:SmokelessProductsMember
2019-01-01
2019-03-31
0000764180
mo:SmokeableProductsMember
2018-01-01
2018-03-31
0000764180
us-gaap:MaterialReconcilingItemsMember
2018-01-01
2018-03-31
0000764180
mo:WineMember
2019-01-01
2019-03-31
0000764180
us-gaap:OperatingSegmentsMember
mo:WineMember
2018-01-01
2018-03-31
0000764180
mo:SmokeableProductsMember
2019-01-01
2019-03-31
0000764180
mo:SmokelessProductsMember
2018-01-01
2018-03-31
0000764180
us-gaap:MaterialReconcilingItemsMember
2019-01-01
2019-03-31
0000764180
us-gaap:AllOtherSegmentsMember
2018-01-01
2018-03-31
0000764180
us-gaap:OperatingSegmentsMember
mo:WineMember
2019-01-01
2019-03-31
0000764180
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-03-31
0000764180
mo:USDenominatedNotesDueTwoThousandFortyNineMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:TermLoanAgreementJUULandCronosMember
2019-02-01
2019-02-28
0000764180
mo:USDenominatedNotesDueTwoThousandTwentyFourMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:USDenominatedNotesDueTwoThousandTwentyNineMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:USDDenominatedNotesMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:EuroDenominatedNotesDueTwoThousandTwentyFiveMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2018-12-31
0000764180
mo:EuroDenominatedNotesMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:USDenominatedNotesDueTwoThousandandTwentyTwoMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:EuroDenominatedNotesDueTwoThousandThirtyOneMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:EuroDenominatedNotesDueTwoThousandTwentyThreeMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:USDenominatedNotesDueTwoThousandTwentySixMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:TermLoanAgreementJUULandCronosMember
2019-01-01
2019-03-31
0000764180
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2019-03-31
0000764180
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2018-12-31
0000764180
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-03-31
0000764180
mo:EuroDenominatedNotesDueTwoThousandTwentySevenMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
us-gaap:SeniorNotesMember
2019-01-01
2019-03-31
0000764180
mo:USDenominatedNotesDueTwoThousandThirtyNineMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:EuroDenominatedNotesMember
us-gaap:SeniorNotesMember
2019-02-01
2019-02-28
0000764180
mo:USDenominatedNotesDueTwoThousandFiftyNineMember
us-gaap:SeniorNotesMember
2019-02-28
0000764180
mo:TermLoanAgreementJUULandCronosMember
2018-12-31
0000764180
2018-01-01
2018-12-31
0000764180
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
2018-04-23
0000764180
mo:IndividualSmokingAndHealthCasesMember
2018-04-23
0000764180
mo:LightsUltraLightsClassActionsMember
2018-04-23
0000764180
mo:IndividualSmokingAndHealthCasesMember
2017-04-27
0000764180
mo:HealthCareCostRecoveryActionsMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:HealthCareCostRecoveryActionsMember
2017-04-27
0000764180
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:IndividualSmokingAndHealthCasesMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
2017-04-27
0000764180
mo:HealthCareCostRecoveryActionsMember
2018-04-23
0000764180
mo:LightsUltraLightsClassActionsMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:LightsUltraLightsClassActionsMember
2017-04-27
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2018NPMAdjustmentsMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:KS
1996-05-01
2019-03-31
0000764180
mo:EngleProgenyCasesStateMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:IA
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:NJ
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAandAltriaGroupMember
mo:HealthCareCostRecoveryActionsMember
country:CA
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:DC
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2013NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:HealthCareCostRecoveryActionsMember
country:CA
us-gaap:ThreatenedLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:OtherDisputesUndertheStateSettlementAgreementsMember
2018-08-01
2018-08-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:OH
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenySmokingandHealthCaseGentileMember
2017-10-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:PA
1996-05-01
2019-03-31
0000764180
mo:EngleProgenyCasesMember
2004-10-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20032015NPMAdjustmentsMember
us-gaap:SettledLitigationMember
2017-10-01
2017-10-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:NY
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:TN
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:CanadianTobaccoManufacturersMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
country:CA
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesFederalMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsMember
us-gaap:SettledLitigationMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenySmokingandHealthCaseCaponeMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20042017Member
us-gaap:SettledLitigationMember
2018-04-01
2018-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2016and2017NPMAdjustmentsMember
us-gaap:SettledLitigationMember
2018-04-01
2018-06-30
0000764180
mo:CreditAgreementMember
us-gaap:RevolvingCreditFacilityMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2010NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:LA
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:USTLitigationMember
stpr:CA
2006-07-01
2006-07-31
0000764180
us-gaap:LetterOfCreditMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:NH
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2003NPMAdjustmentMember
us-gaap:PendingLitigationMember
2013-09-01
2013-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2005NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20042017Member
us-gaap:SettledLitigationMember
us-gaap:SubsequentEventMember
2019-04-01
2019-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:WV
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesReiderandBanksMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2015NPMAdjustmentsMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20042017Member
us-gaap:SettledLitigationMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMember
2006-07-01
2006-07-31
0000764180
mo:ETSSmokingandHealthCaseFlightAttendantsMember
us-gaap:PendingLitigationMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAandAltriaGroupMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
country:CA
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:WV
us-gaap:PendingLitigationMember
2017-01-01
2017-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2012NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:AR
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesDCohenCollarChaconMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:NonEngleProgenySmokingandHealthCaseGentileMember
2017-10-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesWeingartandHancockMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:EngleProgenyCasesStateMember
stpr:FL
2009-06-30
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember
2018-04-01
2018-06-30
0000764180
mo:IndividualSmokingAndHealthCasesMember
stpr:MA
us-gaap:PendingLitigationMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2016and2017NPMAdjustmentsMember
us-gaap:SettledLitigationMember
2019-01-01
2019-03-31
0000764180
mo:HealthCareCostRecoveryActionsMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2008NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsTransitionYears20042017Member
stpr:NY
us-gaap:SettledLitigationMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:MS
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20042017Member
us-gaap:SettledLitigationMember
2018-01-01
2018-12-31
0000764180
mo:EngleProgenyCasesStateMember
mo:AlachuaCountyFloridaMember
2009-06-01
2009-06-30
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:IL
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:MI
1996-05-01
2019-03-31
0000764180
mo:EngleProgenyCasesStateMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20042017Member
us-gaap:SettledLitigationMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:TX
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:LightsMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:MN
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:RI
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:EngleProgenyCasesMember
2000-07-31
0000764180
mo:FederalGovernmentsLawsuitMember
2006-08-01
2006-08-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:OR
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:AK
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:OK
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:CA
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2016and2017NPMAdjustmentsMember
us-gaap:SettledLitigationMember
us-gaap:SubsequentEventMember
2019-04-01
2019-04-25
0000764180
mo:ETSSmokingandHealthCaseFlightAttendantsMember
us-gaap:PendingLitigationMember
2018-03-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions20152017TransitionYearsMember
us-gaap:SettledLitigationMember
2019-01-01
2019-03-31
0000764180
mo:EngleProgenyCasesStateMember
mo:EscambiaCountyFloridaMember
2009-06-01
2009-06-30
0000764180
mo:LightsMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2014NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:IndividualSmokingAndHealthCasesMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:HealthCareCostRecoveryActionsMember
1998-11-01
1998-11-30
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:MO
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:FL
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:IndividualSmokingAndHealthCasesMember
stpr:FL
us-gaap:PendingLitigationMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:NJ
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:OH
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:WV
us-gaap:PendingLitigationMember
2017-01-01
2017-12-31
0000764180
mo:TobaccoandHealthJudgmentMember
2004-10-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2004NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:HealthCareCostRecoveryActionsMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2003NPMAdjustmentMember
us-gaap:CostOfSalesMember
us-gaap:PendingLitigationMember
2013-09-01
2013-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:NV
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:SC
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:PA
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:WV
us-gaap:PendingLitigationMember
2017-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2003NPMAdjustmentMember
mo:MarylandMissouriNewMexicoandPennsylvaniaMember
us-gaap:PendingLitigationMember
2013-09-01
2013-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:FL
1996-05-01
2019-03-31
0000764180
mo:FederalGovernmentsLawsuitMember
mo:ImplementationofCorrectiveCommunicationsMember
2014-01-01
2014-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsMember
2018-04-01
2018-06-30
0000764180
mo:CanadianTobaccoManufacturersMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
country:CA
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesStateMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:WI
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMember
2000-07-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesPollariMember
us-gaap:SubsequentEventMember
2019-04-22
2019-04-22
0000764180
mo:PhilipMorrisUSAandAltriaGroupMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
mo:BritishColumbiaSaskatchewanMember
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2006NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2016NPMAdjustmentsMemberMember
2017-07-01
2017-09-30
0000764180
mo:HealthCareCostRecoveryActionsMember
1998-11-30
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2017NPMAdjustmentsMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2007NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:CA
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesFederalMember
2015-01-01
2015-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:DE
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2003NPMAdjustmentMember
us-gaap:SettledLitigationMember
2013-09-01
2013-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:FL
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:NY
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:CT
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
us-gaap:AssetsMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2009NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActions2011NPMAdjustmentMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:MD
1996-05-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenyCasesMember
stpr:MA
us-gaap:SubsequentEventMember
1999-01-01
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:HealthCareCostRecoveryActionsMember
country:CA
us-gaap:SubsequentEventMember
2019-04-22
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
stpr:LA
1996-05-01
2019-03-31
0000764180
mo:NonEngleProgenySmokingandHealthCaseCaponeMember
2018-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:SmokingAndHealthClassActionsAndAggregatedClaimsLitigationMember
country:PR
1996-05-01
2019-03-31
0000764180
mo:InterestExpenseRelatedToLitigationMember
2019-01-01
2019-03-31
0000764180
mo:TobaccoandHealthJudgmentMember
mo:LitigationCasesResultsMember
2019-01-01
2019-03-31
0000764180
mo:InterestExpenseRelatedToLitigationMember
2018-01-01
2018-03-31
0000764180
mo:TobaccoandHealthJudgmentMember
mo:LitigationCasesResultsMember
2018-01-01
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesKerrivanMember
us-gaap:PendingLitigationMember
2014-10-31
0000764180
mo:EngleProgenyCasesD.BrownMember
us-gaap:PendingLitigationMember
2015-01-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesChadwellMember
us-gaap:PendingLitigationMember
2018-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesSommersMember
us-gaap:PendingLitigationMember
2017-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBryantMember
us-gaap:PendingLitigationMember
2017-12-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesCooperMember
us-gaap:PendingLitigationMember
2015-09-30
0000764180
mo:EngleProgenyCasesNeffMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesKaplanMember
us-gaap:PendingLitigationMember
2018-07-31
0000764180
mo:EngleProgenyCasesChadwellMember
us-gaap:PendingLitigationMember
2018-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMahfuzMember
us-gaap:PendingLitigationMember
2019-02-28
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesHarrisMember
us-gaap:PendingLitigationMember
2014-07-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesHollimanMember
us-gaap:PendingLitigationMember
2019-02-28
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMcCoyMember
us-gaap:PendingLitigationMember
2015-07-31
0000764180
mo:EngleProgenyCasesSommersMember
us-gaap:PendingLitigationMember
2017-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesWallaceMember
us-gaap:PendingLitigationMember
2017-10-31
0000764180
mo:EngleProgenyCasesMcCallMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesTheisMember
us-gaap:PendingLitigationMember
2018-05-31
0000764180
mo:EngleProgenyCasesKaplanMember
us-gaap:PendingLitigationMember
2018-07-31
0000764180
mo:EngleProgenyCasesBryantMember
us-gaap:PendingLitigationMember
2017-12-31
0000764180
mo:EngleProgenyCasesKerrivanMember
us-gaap:PendingLitigationMember
2014-10-31
0000764180
mo:EngleProgenyCasesTheisMember
us-gaap:PendingLitigationMember
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesFreemanMember
us-gaap:PendingLitigationMember
2018-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesNeffMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesLandiMember
us-gaap:PendingLitigationMember
2018-06-30
0000764180
mo:EngleProgenyCasesMahfuzMember
us-gaap:PendingLitigationMember
2019-02-28
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesGlogerMember
us-gaap:PendingLitigationMember
2018-02-28
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesD.BrownMember
us-gaap:PendingLitigationMember
2015-01-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMcCallMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesFrogelMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesR.DouglasMember
us-gaap:PendingLitigationMember
2017-11-30
0000764180
mo:EngleProgenyCasesSantoroMember
us-gaap:PendingLitigationMember
2017-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesSantoroMember
us-gaap:PendingLitigationMember
2017-03-31
0000764180
mo:EngleProgenyCasesHarrisMember
us-gaap:PendingLitigationMember
2014-07-31
0000764180
mo:EngleProgenyCasesGlogerMember
us-gaap:PendingLitigationMember
2018-02-28
0000764180
mo:EngleProgenyCasesMcCoyMember
us-gaap:PendingLitigationMember
2015-07-31
0000764180
mo:EngleProgenyCasesWallaceMember
us-gaap:PendingLitigationMember
2017-10-31
0000764180
mo:EngleProgenyCasesR.DouglasMember
us-gaap:PendingLitigationMember
2017-11-30
0000764180
mo:EngleProgenyCasesFreemanMember
us-gaap:PendingLitigationMember
2018-03-31
0000764180
mo:EngleProgenyCasesFrogelMember
us-gaap:PendingLitigationMember
2019-03-31
0000764180
mo:EngleProgenyCasesCooperMember
us-gaap:PendingLitigationMember
2015-09-30
0000764180
mo:EngleProgenyCasesHollimanMember
us-gaap:PendingLitigationMember
2019-02-28
0000764180
mo:EngleProgenyCasesLandiMember
us-gaap:PendingLitigationMember
2018-06-30
0000764180
mo:CreditAgreementMember
us-gaap:RevolvingCreditFacilityMember
2019-01-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:NonEngleProgenySmokingandHealthCaseCaponeMember
us-gaap:SubsequentEventMember
2019-04-01
2019-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesS.MartinMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBarboseMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBoatrightMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBurkhartMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesSearcyMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesGoreMember
us-gaap:SettledLitigationMember
2018-09-01
2018-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesAhrensMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesAllenMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesSermonsMember
us-gaap:SettledLitigationMember
2018-08-01
2018-08-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesM.BrownMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesLedouxMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesSimonMember
us-gaap:SettledLitigationMember
2018-10-01
2018-10-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesPutneyMember
us-gaap:SettledLitigationMember
2018-09-01
2018-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesMcKeeverMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesJordanMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesPerrottoMember
us-gaap:SettledLitigationMember
2018-09-01
2018-09-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesDanielsonMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBoulterMember
us-gaap:SettledLitigationMember
2019-01-01
2019-01-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesPurdoMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesHowlesMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesJ.BrownMember
us-gaap:SettledLitigationMember
us-gaap:SubsequentEventMember
2019-04-01
2019-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesTognoliMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesL.MartinMember
us-gaap:SettledLitigationMember
us-gaap:SubsequentEventMember
2019-04-01
2019-04-30
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesGriffinMember
us-gaap:SettledLitigationMember
2018-05-01
2018-05-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesPardueMember
us-gaap:SettledLitigationMember
2019-03-01
2019-03-31
0000764180
mo:PhilipMorrisUSAMember
mo:EngleProgenyCasesBergerMember
us-gaap:PendingLitigationMember
2014-09-30
0000764180
mo:EngleProgenyCasesBergerMember
us-gaap:PendingLitigationMember
2014-09-30
0000764180
mo:EngleProgenyCasesBergerMember
us-gaap:PendingLitigationMember
2018-10-01
2018-12-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-03-31
0000764180
srt:ConsolidationEliminationsMember
2019-03-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-03-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-03-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000764180
srt:ConsolidationEliminationsMember
2018-12-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2018-01-01
2018-03-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-01-01
2018-03-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-01-01
2018-03-31
0000764180
srt:ConsolidationEliminationsMember
2018-01-01
2018-03-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-03-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-03-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-03-31
0000764180
srt:ConsolidationEliminationsMember
2019-01-01
2019-03-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2017-12-31
0000764180
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-03-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2017-12-31
0000764180
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2018-03-31
0000764180
srt:ConsolidationEliminationsMember
2018-03-31
0000764180
srt:ConsolidationEliminationsMember
2017-12-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2017-12-31
0000764180
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-03-31
mo:case
mo:year
mo:ruling
iso4217:USD
mo:director
iso4217:CAD
xbrli:shares
mo:manufacture
mo:claim
iso4217:CAD
mo:state
mo:plantiff
mo:board_member
iso4217:EUR
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:shares
xbrli:pure
iso4217:EUR
mo:court
mo:trial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
| |
ý | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2019
OR
|
| |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number 1-08940
Altria Group, Inc.
(Exact name of registrant as specified in its charter)
|
| | |
Virginia | | 13-3260245 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| |
6601 West Broad Street, Richmond, Virginia | | 23230 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code (804) 274-2200
Former name, former address and former fiscal year, if changed since last report
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
| | | | | | |
Large accelerated filer | | þ | | Accelerated filer | | ¨ |
Non-accelerated filer | | ¨ | | Smaller reporting company | | ¨ |
| | | | Emerging growth company | | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
At April 15, 2019, there were 1,870,919,863 shares outstanding of the registrant’s common stock, par value $0.33 1/3 per share.
ALTRIA GROUP, INC.
TABLE OF CONTENTS
|
| | | | |
| | | | |
| | | | Page No. |
PART I - | | FINANCIAL INFORMATION | | |
| | | |
Item 1. | | Financial Statements (Unaudited) | | |
| | | |
| | | | |
| | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
Item 2. | | | | |
| | | | |
Item 3. | | | | |
| | | |
Item 4. | | | | |
| | | |
PART II - | | OTHER INFORMATION | | |
| | | |
Item 1. | | | | |
| | | |
Item 1A. | | | | |
| | | |
Item 2. | | | | |
| | | | |
Item 6. | | | | |
| | | |
Signature | | | | |
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
|
| | | | | | | | |
| | March 31, 2019 | | December 31, 2018 |
Assets | | | | |
Cash and cash equivalents | | $ | 3,352 |
| | $ | 1,333 |
|
Receivables | | 158 |
| | 142 |
|
Inventories: | |
| |
|
Leaf tobacco | | 930 |
| | 940 |
|
Other raw materials | | 190 |
| | 186 |
|
Work in process | | 651 |
| | 647 |
|
Finished product | | 585 |
| | 558 |
|
| | 2,356 |
| | 2,331 |
|
Income taxes | | 3 |
| | 167 |
|
Other current assets | | 393 |
| | 326 |
|
Total current assets | | 6,262 |
| | 4,299 |
|
Property, plant and equipment, at cost | | 4,917 |
| | 4,950 |
|
Less accumulated depreciation | | 2,995 |
| | 3,012 |
|
| | 1,922 |
| | 1,938 |
|
Goodwill | | 5,196 |
| | 5,196 |
|
Other intangible assets, net | | 12,327 |
| | 12,279 |
|
Investments in equity securities | | 32,015 |
| | 30,496 |
|
Other assets | | 1,511 |
| | 1,430 |
|
Total Assets | | $ | 59,233 |
| | $ | 55,638 |
|
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share and per share data)
(Unaudited)
|
| | | | | | | | |
| | March 31, 2019 | | December 31, 2018 |
Liabilities | | | | |
Short-term borrowings | | $ | — |
| | $ | 12,704 |
|
Current portion of long-term debt | | 2,144 |
| | 1,144 |
|
Accounts payable | | 205 |
| | 399 |
|
Accrued liabilities: | | | | |
Marketing | | 490 |
| | 586 |
|
Settlement charges | | 4,367 |
| | 3,454 |
|
Other | | 1,412 |
| | 1,403 |
|
Dividends payable | | 1,501 |
| | 1,503 |
|
Total current liabilities | | 10,119 |
| | 21,193 |
|
Long-term debt | | 27,024 |
| | 11,898 |
|
Deferred income taxes | | 5,353 |
| | 5,172 |
|
Accrued pension costs | | 497 |
| | 544 |
|
Accrued postretirement health care costs | | 1,764 |
| | 1,749 |
|
Other liabilities | | 357 |
| | 254 |
|
Total liabilities | | 45,114 |
| | 40,810 |
|
Contingencies (Note 12) | |
| |
|
Redeemable noncontrolling interest | | 38 |
| | 39 |
|
Stockholders’ Equity | | | | |
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued) | | 935 |
| | 935 |
|
Additional paid-in capital | | 5,943 |
| | 5,961 |
|
Earnings reinvested in the business | | 43,582 |
| | 43,962 |
|
Accumulated other comprehensive losses | | (2,717 | ) | | (2,547 | ) |
Cost of repurchased stock (934,207,054 shares at March 31, 2019 and 931,903,722 shares at December 31, 2018) | | (33,664 | ) | | (33,524 | ) |
Total stockholders’ equity attributable to Altria | | 14,079 |
| | 14,787 |
|
Noncontrolling interests | | 2 |
| | 2 |
|
Total stockholders’ equity | | 14,081 |
| | 14,789 |
|
Total Liabilities and Stockholders’ Equity | | $ | 59,233 |
| | $ | 55,638 |
|
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
|
| | | | | | | | |
| | For the Three Months Ended March 31, |
| | 2019 | | 2018 |
Net revenues | | $ | 5,628 |
| | $ | 6,108 |
|
Cost of sales | | 1,578 |
| | 1,734 |
|
Excise taxes on products | | 1,239 |
| | 1,438 |
|
Gross profit | | 2,811 |
| | 2,936 |
|
Marketing, administration and research costs | | 533 |
| | 618 |
|
Asset impairment and exit costs | | 40 |
| | 2 |
|
Operating income | | 2,238 |
| | 2,316 |
|
Interest and other debt expense, net | | 384 |
| | 166 |
|
Net periodic benefit income, excluding service cost | | (1 | ) | | (7 | ) |
Earnings from equity investment in AB InBev | | (86 | ) | | (342 | ) |
Loss on Cronos-related financial instruments | | 425 |
| | — |
|
Loss on AB InBev/SABMiller business combination | | — |
| | 33 |
|
Earnings before income taxes | | 1,516 |
| | 2,466 |
|
Provision for income taxes | | 395 |
| | 571 |
|
Net earnings | | 1,121 |
| | 1,895 |
|
Net earnings attributable to noncontrolling interests | | (1 | ) | | (1 | ) |
Net earnings attributable to Altria | | $ | 1,120 |
| | $ | 1,894 |
|
Per share data: | | | | |
Basic and diluted earnings per share attributable to Altria | | $ | 0.60 |
| | $ | 1.00 |
|
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
|
| | | | | | | | |
| | For the Three Months Ended March 31, |
| | 2019 | | 2018 |
Net earnings | | $ | 1,121 |
| | $ | 1,895 |
|
Other comprehensive earnings (losses), net of deferred income taxes: | | | | |
Benefit plans | | 29 |
| | 45 |
|
AB InBev | | (199 | ) | | (75 | ) |
Other comprehensive losses, net of deferred income taxes | | (170 | ) | | (30 | ) |
| | | | |
Comprehensive earnings | | 951 |
| | 1,865 |
|
Comprehensive earnings attributable to noncontrolling interests | | (1 | ) | | (1 | ) |
Comprehensive earnings attributable to Altria | | $ | 950 |
| | $ | 1,864 |
|
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity
for the Three Months Ended March 31, 2019 and 2018
(in millions of dollars, except per share data)
(Unaudited)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Attributable to Altria | | | | |
| | Common Stock | | Additional Paid-in Capital | | Earnings Reinvested in the Business | | Accumulated Other Comprehensive Losses | | Cost of Repurchased Stock | | Non-controlling Interests | | Total Stockholders’ Equity |
Balances, December 31, 2018 | | $ | 935 |
| | $ | 5,961 |
| | $ | 43,962 |
| | $ | (2,547 | ) | | $ | (33,524 | ) | | $ | 2 |
| | $ | 14,789 |
|
Net earnings (1) | | — |
| | — |
| | 1,120 |
| | — |
| | — |
| | — |
| | 1,120 |
|
Other comprehensive losses, net of deferred income taxes | | — |
| | — |
| | — |
| | (170 | ) | | — |
| | — |
| | (170 | ) |
Stock award activity | | — |
| | (18 | ) | | — |
| | — |
| | 11 |
| | — |
| | (7 | ) |
Cash dividends declared ($0.80 per share) | | — |
| | — |
| | (1,500 | ) | | — |
| | — |
| | — |
| | (1,500 | ) |
Repurchases of common stock | | — |
| | — |
| | — |
| | — |
| | (151 | ) | | — |
| | (151 | ) |
Balances, March 31, 2019 | | $ | 935 |
| | $ | 5,943 |
| | $ | 43,582 |
| | $ | (2,717 | ) | | $ | (33,664 | ) | | $ | 2 |
| | $ | 14,081 |
|
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Attributable to Altria | | | | |
| | Common Stock | | Additional Paid-in Capital | | Earnings Reinvested in the Business | | Accumulated Other Comprehensive Losses | | Cost of Repurchased Stock | | Non-controlling Interests | | Total Stockholders’ Equity |
Balances, December 31, 2017 | | $ | 935 |
| | $ | 5,952 |
| | $ | 42,251 |
| | $ | (1,897 | ) | | $ | (31,864 | ) | | $ | 3 |
| | $ | 15,380 |
|
Net earnings (1) | | — |
| | — |
| | 1,894 |
| | — |
| | — |
| | — |
| | 1,894 |
|
Other comprehensive losses, net of deferred income taxes | | — |
| | — |
| | — |
| | (30 | ) | | — |
| | — |
| | (30 | ) |
Stock award activity | | — |
| | (14 | ) | | — |
| | — |
| | 9 |
| | — |
| | (5 | ) |
Cash dividends declared ($0.70 per share) | | — |
| | — |
| | (1,329 | ) | | — |
| | — |
| | — |
| | (1,329 | ) |
Repurchases of common stock | | — |
| | — |
| | — |
| | — |
| | (513 | ) | | — |
| | (513 | ) |
Balances, March 31, 2018 | | $ | 935 |
| | $ | 5,938 |
| | $ | 42,816 |
| | $ | (1,927 | ) | | $ | (32,368 | ) | | $ | 3 |
| | $ | 15,397 |
|
(1) $1 million due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars, which is reported in the mezzanine equity section on the condensed consolidated balance sheets.
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
|
| | | | | | | | |
| | For the Three Months Ended March 31, |
| | 2019 | | 2018 |
Cash Provided by (Used in) Operating Activities | | | | |
Net earnings | | $ | 1,121 |
| | $ | 1,895 |
|
Adjustments to reconcile net earnings to operating cash flows: | | | | |
Depreciation and amortization | | 53 |
| | 53 |
|
Deferred income tax (benefit) provision | | (72 | ) | | 54 |
|
Earnings from equity investment in AB InBev | | (86 | ) | | (342 | ) |
Loss on AB InBev/SABMiller business combination | | — |
| | 33 |
|
Loss on Cronos-related financial instruments | | 425 |
| | — |
|
Asset impairment and exit costs, net of cash paid | | 17 |
| | (7 | ) |
Cash effects of changes: | | | | |
Receivables | | (16 | ) | | 9 |
|
Inventories | | (25 | ) | | (30 | ) |
Accounts payable | | (189 | ) | | (164 | ) |
Income taxes | | 471 |
| | 521 |
|
Accrued liabilities and other current assets | | (513 | ) | | (267 | ) |
Accrued settlement charges | | 913 |
| | 1,018 |
|
Pension plan contributions | | (3 | ) | | (7 | ) |
Pension provisions and postretirement, net | | (8 | ) | | — |
|
Other, net | | 201 |
| | 43 |
|
Net cash provided by operating activities | | 2,289 |
| | 2,809 |
|
Cash Used in Investing Activities | | | | |
Capital expenditures | | (38 | ) | | (34 | ) |
Investment in Cronos | | (1,831 | ) | | — |
|
Other, net | | (81 | ) | | (7 | ) |
Net cash used in investing activities | | $ | (1,950 | ) | | $ | (41 | ) |
Altria Group, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
|
| | | | | | | | |
| | For the Three Months Ended March 31, |
| | 2019 | | 2018 |
Cash Provided by (Used in) Financing Activities | | | | |
Repayment of short-term borrowings | | $ | (12,800 | ) | | $ | — |
|
Long-term debt issued | | 16,265 |
| | — |
|
Repurchases of common stock | | (151 | ) | | (513 | ) |
Dividends paid on common stock | | (1,502 | ) | | (1,257 | ) |
Other | | (129 | ) | | (23 | ) |
Net cash provided by (used in) financing activities | | 1,683 |
| | (1,793 | ) |
Cash, cash equivalents and restricted cash: | | | | |
Increase | | 2,022 |
| | 975 |
|
Balance at beginning of period | | 1,433 |
| | 1,314 |
|
Balance at end of period | | $ | 3,455 |
| | $ | 2,289 |
|
| | | | |
The following table provides a reconciliation of cash, cash equivalents and restricted cash to the amounts reported on Altria’s condensed consolidated balance sheets: |
| | At March 31, 2019 | | At December 31, 2018 |
Cash and cash equivalents | | $ | 3,352 |
| | $ | 1,333 |
|
Restricted cash included in other current assets (1) | | 68 |
| | 57 |
|
Restricted cash included in other assets (1) | | 35 |
| | 43 |
|
Cash, cash equivalents and restricted cash | | $ | 3,455 |
| | $ | 1,433 |
|
(1) Note 12. Contingencies.
See notes to condensed consolidated financial statements.
Altria Group, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation:
Background
At March 31, 2019, Altria Group, Inc.’s (“Altria”) wholly-owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly-owned subsidiary of PM USA; Sherman Group Holdings, LLC and its subsidiaries (“Nat Sherman”), which are engaged in the manufacture and sale of super premium cigarettes and the sale of premium cigars; UST LLC (“UST”), which through its wholly-owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of smokeless tobacco products and wine; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases. In December 2018, Altria announced the decision to refocus its innovative product efforts, which included the discontinuation of production and distribution of all e-vapor products by Nu Mark LLC (“Nu Mark”). Prior to that time, Nu Mark was engaged in the manufacture and sale of innovative tobacco products. Other Altria wholly-owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly-owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At March 31, 2019, Altria’s principal wholly-owned subsidiaries were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests.
At March 31, 2019, Altria had a 10.1% economic and voting interest of Anheuser-Busch InBev SA/NV (“AB InBev”), which Altria accounts for under the equity method of accounting using a one-quarter lag. Altria receives cash dividends on its interest in AB InBev and will continue to do so as long as AB InBev pays dividends.
In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of non-voting convertible common stock of JUUL Labs, Inc. (“JUUL”), the U.S. leader in e-vapor, representing a 35% economic interest for $12.8 billion. JUUL is engaged in the manufacture and sale of e-vapor products globally. If and when antitrust clearance is obtained, Altria’s non-voting shares will automatically convert to voting shares (“Share Conversion”). At March 31, 2019, Altria had a 35% economic interest in JUUL, which Altria accounts for as an investment in an equity security. Upon Share Conversion, Altria expects to account for its investment in JUUL under the equity method of accounting. Altria has agreed to non-competition obligations generally requiring that it participate in the e-vapor business only through JUUL as long as Altria is supplying JUUL services, which Altria is committed to doing for at least six years.
On March 8, 2019, Altria, through a subsidiary, completed its acquisition of a 45% economic and voting interest in Cronos Group Inc. (“Cronos”), a global cannabinoid company headquartered in Toronto, Canada. At March 31, 2019, Altria had a 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting using a one-quarter lag. As a result of the one-quarter lag, no earnings/losses from Altria’s equity investment in Cronos were recorded for the quarter ended March 31, 2019.
For further discussion of Altria’s investments in equity securities, see Note 4. Investments in Equity Securities.
Share Repurchases
In July 2015, Altria’s Board of Directors (the “Board of Directors”) authorized a $1.0 billion share repurchase program that it expanded to $3.0 billion in October 2016 and to $4.0 billion in July 2017 (as expanded, the “July 2015 share repurchase program”). In January 2018, Altria completed the July 2015 share repurchase program, under which it purchased a total of 58.7 million shares of its common stock at an average price of $68.15 per share.
Following the completion of the July 2015 share repurchase program, the Board of Directors authorized a new $1.0 billion share repurchase program in January 2018 that it expanded to $2.0 billion in May 2018 (as expanded, the “January 2018 share
repurchase program”). At March 31, 2019, Altria had $195 million remaining in the January 2018 share repurchase program. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board of Directors.
Altria’s share repurchase activity was as follows:
|
| | | | | | | | |
| | For the Three Months Ended March 31, |
| | 2019 | | 2018 |
| | (in millions, except per share data) |
Total number of shares repurchased | | 2.7 |
| | 8.0 |
|
Aggregate cost of shares repurchased | | $ | 151 |
| | $ | 513 |
|
Average price per share of shares repurchased | | $ | 56.34 |
| | $ | 64.33 |
|
Basis of Presentation
The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year.
These statements should be read in conjunction with the consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2018.
On January 1, 2019, Altria adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) and all related ASU amendments (collectively “ASU No. 2016-02”), which requires entities to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. Altria has elected to apply the guidance retrospectively at the beginning of the period of adoption. As a result, comparative periods prior to adoption will continue to be presented in accordance with prior lease guidance, including disclosures. The impact of the adoption was not material to Altria’s consolidated financial statements. As a result of the adoption, Altria and its subsidiaries, as lessees, recorded right-of-use assets and lease liabilities of $179 million at January 1, 2019 for its leases, which were all operating leases. There was no cumulative effect adjustment to the opening balance of earnings reinvested in the business. Right-of-use assets and lease liabilities on Altria’s condensed consolidated balance sheet at March 31, 2019 were not materially different than the amounts recorded upon adoption of ASU No. 2016-02.
Additionally, in accordance with ASU No. 2016-02, lessor accounting for leveraged leases that commenced before the January 1, 2019 adoption date of ASU No. 2016-02 is unchanged unless there is a change in the scope of, or the consideration for, such leases. As a result, adoption of ASU No. 2016-02 as it relates to PMCC’s leveraged leases had no impact on Altria’s financial statements at the adoption date. During the first three months of 2019, PMCC had no new leases nor any changes in the scope of or the consideration for its existing leveraged leases.
For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 14. New Accounting Guidance Not Yet Adopted.
Note 2. Revenues from Contracts with Customers:
Altria disaggregates net revenues based on product type. For further discussion, see Note 9. Segment Reporting.
Altria’s businesses offer cash discounts to customers for prompt payment and calculate cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Altria’s businesses record an allowance for cash discounts, which is included as a contra-asset against receivables on Altria’s condensed consolidated balance sheets. There was no allowance for cash discounts at March 31, 2019 and December 31, 2018, and there were no differences between amounts recorded as an allowance for cash discounts and cash discounts subsequently given to customers.
Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $233 million and $288 million at March 31, 2019 and December
31, 2018, respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At March 31, 2019 and December 31, 2018, there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue.
Receivables, which primarily reflect sales of wine produced and/or distributed by Ste. Michelle, were $158 million and $142 million at March 31, 2019 and December 31, 2018, respectively. At March 31, 2019 and December 31, 2018, there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables.
Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, due to the limited shelf life of USSTC’s smokeless tobacco products it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return.
Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows:
Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas.
Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements.
These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.
Note 3. Asset Impairment, Exit and Implementation Costs:
Pre-tax asset impairment, exit and implementation costs consisted of the following:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| For the Three Months Ended March 31, 2019 | | For the Three Months Ended March 31, 2018 |
| Asset Impairment and Exit Costs | | Implementation Costs (1) | | Total | | Asset Impairment and Exit Costs | | Implementation Costs (2) | | Total |
| (in millions) |
Smokeable products | $ | 36 |
| | $ | 8 |
| | $ | 44 |
| | $ | — |
| | $ | 1 |
| | $ | 1 |
|
Smokeless products | 8 |
| | 1 |
| | 9 |
| | 2 |
| | — |
| | 2 |
|
All other | (5 | ) | | — |
| | (5 | ) | | — |
| | — |
| | — |
|
General corporate | 1 |
| | — |
| | 1 |
| | — |
| | — |
| | — |
|
Total | 40 |
| | 9 |
| | 49 |
| | 2 |
| | 1 |
| | 3 |
|
Plus amounts included in net periodic benefit income, excluding service cost (3) | 12 |
| | — |
| | 12 |
| | — |
| | — |
| | — |
|
Total | $ | 52 |
| | $ | 9 |
| | $ | 61 |
| | $ | 2 |
| | $ | 1 |
| | $ | 3 |
|
(1) Included in marketing, administration and research costs in Altria’s condensed consolidated statement of earnings.
(2) Included in cost of sales in Altria’s condensed consolidated statements of earnings.
(3) Represents curtailment costs. See Note 6. Benefit Plans.
The 2019 pre-tax asset impairment, exit and implementation costs are related to the cost reduction program discussed below.
The movement in the restructuring liabilities, substantially all of which are severance liabilities, was as follows:
|
| | | |
| For the Three Months Ended March 31, 2019 |
| (in millions) |
Balances at December 31, 2018 | $ | 155 |
|
Charges | 40 |
|
Cash spent | (35 | ) |
Balances at March 31, 2019 | $ | 160 |
|
Cost Reduction Program
In December 2018, Altria announced a cost reduction program that includes, among other things, reducing third-party spending and workforce reductions across the businesses. As a result of the cost reduction program, Altria expects to record total pre-tax restructuring charges of approximately $210 million. Of this amount, Altria incurred pre-tax charges of $121 million in 2018 and expects to record the remainder in 2019. The total estimated charges, substantially all of which will result in cash expenditures, relate primarily to employee separation costs of approximately $180 million and other costs of approximately $30 million. Total pre-tax charges incurred since the inception of this cost reduction program were $182 million. Cash payments related to this cost reduction program of $22 million were made during the three months ended March 31, 2019. There were no cash payments related to this program in 2018.
Note 4. Investments in Equity Securities:
Altria’s investments consisted of the following:
|
| | | | | | | | |
| | Carrying Amount |
| | March 31, 2019 | | December 31, 2018 |
| | (in millions) |
AB InBev | | $ | 17,476 |
| | $ | 17,696 |
|
JUUL | | 12,800 |
| | 12,800 |
|
Cronos (1) | | 1,739 |
| | — |
|
Total | | $ | 32,015 |
| | $ | 30,496 |
|
(1) Includes investment in Acquired Common Shares ($397 million), the Cronos warrant ($949 million) and the Fixed-price Preemptive Rights ($393 million) as discussed further below.
Investment in AB InBev
At March 31, 2019, Altria had a 10.1% economic and voting interest of AB InBev, consisting of 185 million restricted shares of AB InBev (the “Restricted Shares”) and 12 million ordinary shares of AB InBev. Altria accounts for its investment in AB InBev under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of AB InBev, including having active representation on AB InBev’s Board of Directors (“AB InBev Board”) and certain AB InBev Board committees. Through this representation, Altria participates in AB InBev policy making processes.
At December 31, 2018, AB InBev had derivative financial instruments used to hedge the share price related to 92.4 million of its share commitments. AB InBev’s share price in Euros at March 31, 2019 and December 31, 2018 was €74.76 and €57.70, respectively. Consistent with the one-quarter lag for reporting AB InBev’s results in Altria’s financial results, Altria will record its share of AB InBev’s first quarter 2019 mark-to-market gains associated with these derivative financial instruments in the second quarter of 2019.
Altria reviews its investment in AB InBev for impairment by comparing the fair value of its investment to its carrying value. If the carrying value of Altria’s investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, AB InBev’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in AB InBev until recovery.
The fair value of Altria’s equity investment in AB InBev is based on: (i) unadjusted quoted prices in active markets for AB InBev’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder forecloses on the Restricted Shares, the relevant Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
The fair value of Altria’s equity investment in AB InBev at March 31, 2019 and December 31, 2018 was $16.6 billion and $13.1 billion, respectively, compared with its carrying value of $17.5 billion and $17.7 billion, respectively. At March 31, 2019, the fair value of Altria’s equity investment in AB InBev was less than its carrying value by 5%, as compared to 26% at December 31, 2018. At April 18, 2019, the fair value of Altria’s equity investment in AB InBev approximated its carrying value. Based on Altria’s evaluation of the factors identified above, Altria concluded that the decline in fair value of its investment in AB InBev below its carrying value at March 31, 2019 is temporary and, therefore, Altria has not recorded any impairment.
Investment in JUUL
In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of JUUL’s non-voting Class C-1 Common Stock for an aggregate price of $12.8 billion, which will convert automatically to shares of voting Class C Common Stock upon antitrust clearance, and a security convertible into additional shares of Class C-1 Common Stock or Class C Common Stock, as applicable, for no additional payment upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”). At March 31, 2019, Altria owned 35% of the issued and outstanding capital stock of JUUL.
Upon Share Conversion, Altria will possess 35% of JUUL’s outstanding voting power, except to the extent that Altria’s percentage ownership has decreased, and have the right to designate one-third of the members of the JUUL Board of Directors, subject to proportionate downward adjustment if Altria’s percentage ownership falls below 30%.
Altria received a broad preemptive right to purchase JUUL shares to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares for six years from December 20, 2018.
At March 31, 2019, Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no such upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes since the JUUL Transaction. Upon Share Conversion, Altria expects to account for its investment in JUUL under the equity method of accounting.
Investment in Cronos
On March 8, 2019, Altria, through a subsidiary, completed its acquisition of:
| |
▪ | 149.8 million newly issued common shares of Cronos (“Acquired Common Shares”), representing a 45% economic and voting interest. |
| |
▪ | anti-dilution protections to purchase Cronos common shares to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of CAD $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of March 31, 2019, Altria estimates the Fixed-price Preemptive Rights will allow Altria to purchase up to an additional approximately 40 million common shares of Cronos. |
| |
▪ | a warrant providing Altria the ability to purchase up to an additional approximately 74 million common shares of Cronos at a per share exercise price of CAD $19.00, which expires on March 8, 2023. |
The total purchase price for the Acquired Common Shares, Fixed-price Preemptive Rights and warrant (collectively, “Investment in Cronos”) was CAD $2.4 billion (USD $1.8 billion). Upon full exercise of the Fixed-price Preemptive Rights, to the extent such rights become available, and the warrant, Altria would own a maximum of 55% of the outstanding common shares of Cronos.
In accounting for the acquisition of these assets as of the date of closing, the Fixed-price Preemptive Rights and warrant were recorded at each of their fair values using Black-Scholes option-pricing models, based on the assumptions described in Note 5. Financial Instruments. In addition, a deferred tax liability related to the Fixed-price Preemptive Rights and warrant was recorded. The residual of the purchase price was allocated to the Acquired Common Shares. Accordingly, the CAD $2.4 billion (USD $1.8 billion) purchase price was recorded in USD as follows:
| |
▪ | $1.2 billion to the warrant; |
| |
▪ | $0.5 billion to the Fixed-price Preemptive Rights; |
| |
▪ | $0.4 billion to the Acquired Common Shares; and |
| |
▪ | $0.3 billion to a deferred tax liability. |
For a discussion of derivatives related to Altria’s Investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 5. Financial Instruments.
At March 31, 2019, Altria had a 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period. As a result of the one-quarter lag, no earnings/losses from Altria’s equity investment in Cronos were recorded for the quarter ended March 31, 2019.
Altria nominated four directors, including one director who is independent from Altria, who were elected to serve on Cronos’s seven member Board of Directors.
Note 5. Financial Instruments:
Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes.
Altria’s investment in AB InBev, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively “foreign currency contracts”), and Euro denominated notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in AB InBev.
At March 31, 2019 and December 31, 2018, Altria had foreign currency contracts with aggregate notional amounts of $1,226 million. At March 31, 2019, Altria had foreign currency denominated debt with an aggregate fair value and carrying value of $4,851 million and $4,740 million, respectively. At December 31, 2018, Altria had no foreign currency denominated debt.
Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and nonperformance risk is included in the fair values of foreign currency contracts. See Note 10. Debt for a discussion of the fair value hierarchy related to Altria’s debt.
Altria’s Fixed-price Preemptive Rights and warrant related to its investment in Cronos, which is further discussed in Note 4. Investments in Equity Securities, are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and warrant are estimated using Black-Scholes option-pricing models, adjusted for unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at:
|
| | | | | | | | |
| | March 31, 2019 | | March 8, 2019 | | March 31, 2019 | | March 8, 2019 |
| | Fixed-price Preemptive Rights | | Warrant |
Expected life (1) | | 2.27 years | | 2.32 years | | 3.94 years | | 4 years |
Expected volatility (2) | | 92.86% | | 93.02% | | 92.86% | | 93.02% |
Risk-free interest rate (3)(4) | | 1.54% | | 1.61% | | 1.52% | | 1.67% |
Expected dividend yield (5) | | —% | | —% | | —% | | —% |
(1) Based on the weighted-average remaining expected life of the Fixed-price Preemptive Rights (with a range from 1.75 years to 7 years) and the March 8, 2023 expiration date of the warrant.
(2) Based on a blend of historical volatility levels of the underlying equity security and peer companies.
(3) Based on the implied yield currently available on Canadian Treasury zero coupon issues weighted for the remaining expected life of the Fixed-price Preemptive Rights.
(4) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the warrant.
(5) Based on Cronos’s expected dividend payments.
The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and warrant, which are classified in Level 3 of the fair value hierarchy:
|
| | | | |
| | (in millions) |
Balance at December 31, 2018 | | $ | — |
|
Investment in Fixed-price Preemptive Rights and warrant | | 1,736 |
|
Pre-tax losses recognized in net earnings | | (394 | ) |
Balance at March 31, 2019 | | $ | 1,342 |
|
Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows:
|
| | | | | | | | | | | | | | | | | | |
| Fair Value of Assets | | Fair Value of Liabilities |
| Balance Sheet Classification | | March 31, 2019 | | December 31, 2018 | | Balance Sheet Classification | March 31, 2019 | | December 31, 2018 |
Derivatives designated as hedging instruments: | (in millions) |
Foreign currency contracts | Other current assets | | $ | 48 |
| | $ | 37 |
| | Other accrued liabilities | $ | — |
| | $ | — |
|
Foreign currency contracts | Other assets | | 15 |
| | 4 |
| | Other liabilities | — |
| | 4 |
|
Total | | $ | 63 |
| | |